middle.news
How Alterity’s ATH434 Could Transform Treatment for Multiple System Atrophy
2:38pm on Wednesday 30th of July, 2025 AEST
•
Biotechnology
Read Story
How Alterity’s ATH434 Could Transform Treatment for Multiple System Atrophy
2:38pm on Wednesday 30th of July, 2025 AEST
Key Points
FDA Fast Track designation granted for ATH434 in Multiple System Atrophy
Positive Phase 2 trial data demonstrating slowed disease progression and symptom improvement
ATH434 shows favorable safety and target engagement in neuroimaging biomarkers
Company ends Q4 FY25 with A$40.66 million cash and recent A$26.3 million capital raise
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ALTERITY THERAPEUTICS (ASX:ATH)
OPEN ARTICLE